www.esh.org - info@esh.org 1
PROGRAMME ON DEMAND
2nd How to Diagnose and Treat
ACUTE LEUKAEMIA
Virtual Conference - #ESHAL2020
June 30 – July 2, 2020
Chairs : Hervé Dombret, Arnold Ganser, Jorge Sierra, Wendy Stock
The pre-recorded Case based lectures will be available “on demand” as of Saturday, June 20, 2020. The other
sessions will be recorded “live”, as they take place, and will be available “on demand” as soon as they are
over.
By the end of the meeting and until July 12, 2020, the full scientific programme will be available on the e-
Platform “on demand” to enable registered participants to view all presentations and discussions at times
convenient to them, regardless of their time zone.
15' Welcome
15' Keynote lecture - COVID 19 Jorge Sierra (Barcelona)
10' Discussion
95' Rare subsets of acute leukaemia
Chair: Gail Roboz (New York)
20' Case-based lecture : Charles Mullighan (Memphis)
Mixed phenotype acute leukaemias (B/M)
20' Case-based lecture : Jonathan Bond (Dublin)
Interface acute leukaemias (T/M)
20' Case-based lecture : Lucy Godley (Chicago)
Germline predisposition to AML
Brief oral communication
5' Dasatinib inhibits FLT3/itd and PTPN11 mutated Nathali Kaushansky (Rehovot)
acute myeloid leukemia cells overexpressing SRC Tyrosine kinases
30' Panel discussion
95' Tracking leukaemic stem cells (LSCs)
Chair: Sylvie Freeman (Birmingham)
20' Case-based lecture : Tracy Murphy (Toronto)
LSC signature
SCIENTIFIC
PROGRAMME
RARE SUBSETS OF
ACUTE LEUKAEMIA
TRACKING LEUKAEMIC
STEM CELLS (LSCs)
ROUTINE DIAGNOSIS
GENE EXPRESSION
AND MUTATIONAL
PROFILING
DEBATE 1 – ALL
PATIENTS WITH
INTERMEDIATE-RISK
AML MUST BE
TRANSPLANTED
INTERACTIVE
CASES 1 – MUTATION-BASED
THERAPY
OFF-LABEL
ROUNDTABLE –
SHOULD WE REALLY
USE NEW TARGETED
INHIBITORS AS SINGLE
AGENTS ?
ADDITION OF A 3RD
AGENT TO FRONTLINE
7+3
ROUNDTABLE –
CURATIVE OPTIONS
FOR OLDER AML
INTERACTIVE CASES 2
DEBATE 2 - BEST
TREATMENT FOR
NPM1-MUTATED AML IN
THE NEXT FUTURE ?
ALLOGENEIC
HAEMATOPOIETIC
STEM CELL
TRANSPLANTATION
(HSCT)
IMMUNOTHERAPY FOR
ACUTE LEUKAEMIA
DEBATE 3 - T-ALL:
WHERE ARE WE GOING
NOW?
SELECTED ABSTRACTS
AND CLINICAL
CASES FOR AN ORAL
PRESENTATION
SELECTED ABSTRACTS
FOR A POSTER
PRESENTATION
DISCLOSURES